Mustargen, Ledaga(mechlorethamine)
Ledaga, Valchlor (mechlorethamine) is a small molecule pharmaceutical. Mechlorethamine was first approved as Mustargen on 1982-01-01. It is used to treat hodgkin disease, malignant pleural effusion, mycosis fungoides, and neoplasm metastasis in the USA. It has been approved in Europe to treat mycosis fungoides.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Valchlor (discontinued: Mustargen)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mechlorethamine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VALCHLOR | Helsinn Birex Pharmaceuticals | N-202317 RX | 2013-08-23 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| valchlor | New Drug Application | 2024-11-20 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J9230 | Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg |
Clinical
Clinical Trials
4903 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 345 | 737 | 173 | 14 | 54 | 1152 |
| Leukemia | D007938 | — | C95 | 255 | 473 | 126 | 18 | 43 | 802 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 109 | 354 | 176 | 13 | 44 | 631 |
| Multiple myeloma | D009101 | — | C90.0 | 200 | 362 | 65 | 8 | 25 | 570 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 181 | 310 | 66 | 3 | 21 | 489 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 143 | 247 | 67 | 17 | 20 | 429 |
| Plasma cell neoplasms | D054219 | — | — | 146 | 267 | 53 | 6 | 18 | 419 |
| Lymphoid leukemia | D007945 | — | C91 | 117 | 205 | 66 | 17 | 15 | 373 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 122 | 201 | 48 | 3 | 11 | 326 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 107 | 181 | 59 | 4 | 12 | 322 |
Show 62 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 221 | 176 | 25 | — | 21 | 368 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 100 | 157 | 32 | — | 12 | 263 |
| Myeloid leukemia | D007951 | — | C92 | 59 | 121 | 26 | — | 10 | 192 |
| Recurrence | D012008 | — | — | 79 | 88 | 12 | — | 6 | 153 |
| Melanoma | D008545 | — | — | 88 | 83 | 6 | — | 6 | 151 |
| Hematologic neoplasms | D019337 | — | — | 58 | 83 | 7 | — | 8 | 133 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 69 | 71 | 10 | — | 2 | 122 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 34 | 83 | 4 | — | 11 | 121 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 50 | 47 | 22 | — | 7 | 117 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 24 | 86 | 8 | — | 6 | 111 |
Show 231 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 26 | 18 | — | — | 2 | 37 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 13 | 20 | — | — | 8 | 37 |
| Mycosis fungoides | D009182 | — | C84.0 | 12 | 19 | — | — | 9 | 37 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 9 | 22 | — | — | 3 | 28 |
| Mycoses | D009181 | — | B35-B49 | 8 | 18 | — | — | 5 | 28 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 20 | 13 | — | — | 1 | 26 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 9 | 14 | — | — | 2 | 22 |
| Myeloid leukemia accelerated phase | D015465 | — | — | 5 | 17 | — | — | 1 | 21 |
| Sezary syndrome | D012751 | — | C84.1 | 8 | 11 | — | — | 3 | 20 |
| Mesothelioma | D008654 | — | C45 | 16 | 11 | — | — | 1 | 19 |
Show 272 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pinealoma | D010871 | — | — | 6 | — | — | — | — | 6 |
| Muscle weakness | D018908 | — | — | 2 | — | — | — | 1 | 3 |
| Adrenocortical carcinoma | D018268 | — | — | 3 | — | — | — | — | 3 |
| Nervous system diseases | D009422 | — | G00-G99 | 3 | — | — | — | — | 3 |
| Papillary thyroid cancer | D000077273 | — | — | 2 | — | — | — | — | 2 |
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 2 | — | — | — | — | 2 |
| Neuroepithelial neoplasms | D018302 | — | — | 2 | — | — | — | — | 2 |
| Optic nerve glioma | D020339 | — | — | 2 | — | — | — | — | 2 |
| Lysosomal storage diseases | D016464 | — | — | 1 | — | — | — | 1 | 2 |
| Ductal carcinoma | D044584 | — | — | 2 | — | — | — | — | 2 |
Show 58 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 4 | 4 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 4 | 4 |
| Blood circulation | D001775 | — | — | — | — | — | — | 3 | 3 |
| Hemoglobin sc disease | D006450 | EFO_1001797 | D57.2 | — | — | — | — | 2 | 2 |
| Dysmenorrhea | D004412 | — | N94.6 | — | — | — | — | 2 | 2 |
| Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | — | — | — | 2 | 2 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | — | 2 | 2 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 2 | 2 |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | — | — | — | — | 2 | 2 |
| Chronic pain | D059350 | — | — | — | — | — | — | 2 | 2 |
Show 76 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mechlorethamine |
| INN | chlormethine |
| Description | Mechlorethamine is a nitrogen mustard and an organochlorine compound. It has a role as an alkylating agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(CCCl)CCCl |
Identifiers
| PDB | — |
| CAS-ID | 51-75-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL427 |
| ChEBI ID | 28925 |
| PubChem CID | 4033 |
| DrugBank | DB00888 |
| UNII ID | 50D9XSG0VR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,827 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use